NEUROCRINE BIOSCIENCES INC Selling, General and Administrative Expense
NEUROCRINE BIOSCIENCES INC (NBIX) reported Selling, General and Administrative Expense of $439.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for the quarter ending 2026-06-30 was $439.70M, a 53.58% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for the quarter ending 2026-03-31 was $318.50M, a 15.19% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for the quarter ending 2025-12-31 was $301.80M, a 4.86% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for the quarter ending 2025-09-30 was $291.60M, a 24.46% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for fiscal 2025 was $1.16B, a 14.79% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for fiscal 2024 was $1.01B, a 13.47% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for fiscal 2023 was $887.60M, a 17.92% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC selling, general and administrative expense for fiscal 2022 was $752.70M, a 29.04% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $439.70M 10-Q · filed 2026-07-31 | $758.20M 10-Q · filed 2026-07-31 | $1.06B derived: sum of 3 quarters · filed 2026-07-31 | $1.35B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $318.50M 10-Q · filed 2026-05-05 | $620.30M derived: sum of 2 quarters · filed 2026-05-05 | $911.90M derived: sum of 3 quarters · filed 2026-05-05 | $1.20B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $301.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $593.40M derived: sum of 2 quarters · filed 2026-02-11 | $879.70M derived: sum of 3 quarters · filed 2026-07-31 | $1.16B 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $291.60M 10-Q · filed 2025-10-28 | $577.90M derived: sum of 2 quarters · filed 2026-07-31 | $854.40M 10-Q · filed 2025-10-28 | $1.14B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $286.30M 10-Q · filed 2026-07-31 | $562.80M 10-Q · filed 2026-07-31 | $850.60M derived: sum of 3 quarters · filed 2026-07-31 | $1.08B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $276.50M 10-Q · filed 2026-05-05 | $564.30M derived: sum of 2 quarters · filed 2026-05-05 | $798.60M derived: sum of 3 quarters · filed 2026-05-05 | $1.04B derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $287.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $522.10M derived: sum of 2 quarters · filed 2026-02-11 | $764.10M derived: sum of 3 quarters · filed 2026-02-11 | $1.01B 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $234.30M 10-Q · filed 2025-10-28 | $476.30M derived: sum of 2 quarters · filed 2025-10-28 | $719.40M 10-Q · filed 2025-10-28 | $938.30M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $242.00M 10-Q · filed 2025-07-30 | $485.10M 10-Q · filed 2025-07-30 | $704.00M derived: sum of 3 quarters · filed 2026-02-11 | $908.20M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $243.10M 10-Q · filed 2025-05-05 | $462.00M derived: sum of 2 quarters · filed 2026-02-11 | $666.20M derived: sum of 3 quarters · filed 2026-02-11 | $888.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $218.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $423.10M derived: sum of 2 quarters · filed 2026-02-11 | $644.90M derived: sum of 3 quarters · filed 2026-02-11 | $887.60M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $204.20M 10-Q · filed 2024-10-30 | $426.00M derived: sum of 2 quarters · filed 2024-10-30 | $668.70M 10-Q · filed 2024-10-30 | $851.60M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-06-30 | $221.80M 10-Q · filed 2024-08-01 | $464.50M 10-Q · filed 2024-08-01 | $647.40M derived: sum of 3 quarters · filed 2025-02-10 | $833.70M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-03-31 | $242.70M 10-Q · filed 2024-05-01 | $425.60M derived: sum of 2 quarters · filed 2025-02-10 | $611.90M derived: sum of 3 quarters · filed 2025-02-10 | $794.70M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2022-12-31 | $182.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $369.20M derived: sum of 2 quarters · filed 2025-02-10 | $552.00M derived: sum of 3 quarters · filed 2025-02-10 | $752.70M 10-K · filed 2025-02-10 | ||||
| 2022-09-30 | $186.30M 10-Q · filed 2023-10-31 | $369.10M derived: sum of 2 quarters · filed 2023-10-31 | $569.80M 10-Q · filed 2023-10-31 | $726.30M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $182.80M 10-Q · filed 2023-08-01 | $383.50M 10-Q · filed 2023-08-01 | $540.00M derived: sum of 3 quarters · filed 2024-02-09 | $694.60M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | $200.70M 10-Q · filed 2023-05-03 | $357.20M derived: sum of 2 quarters · filed 2024-02-09 | $511.80M derived: sum of 3 quarters · filed 2024-02-09 | $655.00M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | $156.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $311.10M derived: sum of 2 quarters · filed 2024-02-09 | $454.30M derived: sum of 3 quarters · filed 2024-02-09 | $583.30M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | $154.60M 10-Q · filed 2022-11-01 | $297.80M derived: sum of 2 quarters · filed 2022-11-01 | $426.80M 10-Q · filed 2022-11-01 | $533.30M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $143.20M 10-Q · filed 2022-08-04 | $272.20M 10-Q · filed 2022-08-04 | $378.70M derived: sum of 3 quarters · filed 2023-02-09 | $491.20M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $129.00M 10-Q · filed 2022-05-04 | $235.50M derived: sum of 2 quarters · filed 2023-02-09 | $348.00M derived: sum of 3 quarters · filed 2023-02-09 | $444.50M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $106.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $219.00M derived: sum of 2 quarters · filed 2023-02-09 | $315.50M derived: sum of 3 quarters · filed 2023-02-09 | $433.30M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $112.50M 10-Q · filed 2021-11-01 | $209.00M derived: sum of 2 quarters · filed 2021-11-01 | $326.80M 10-Q · filed 2021-11-01 | $428.10M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-06-30 | $96.50M 10-Q · filed 2021-08-03 | $214.30M 10-Q · filed 2021-08-03 | $315.60M derived: sum of 3 quarters · filed 2022-02-11 | $400.10M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-03-31 | $117.80M 10-Q · filed 2021-05-05 | $219.10M derived: sum of 2 quarters · filed 2022-02-11 | $303.60M derived: sum of 3 quarters · filed 2022-02-11 | $384.40M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2019-12-31 | $101.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $185.80M derived: sum of 2 quarters · filed 2022-02-11 | $266.60M derived: sum of 3 quarters · filed 2022-02-11 | $354.10M 10-K · filed 2022-02-11 | $354.06M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $84.50M 10-Q · filed 2020-11-09 | $84.49M 10-Q · filed 2019-11-04 | $165.30M derived: sum of 2 quarters · filed 2020-11-09 | $252.80M 10-Q · filed 2020-11-09 | $252.85M 10-Q · filed 2019-11-04 | $321.75M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-06-30 | $80.80M 10-Q · filed 2020-08-03 | $80.82M 10-Q · filed 2019-07-29 | $168.30M 10-Q · filed 2020-08-03 | $168.36M 10-Q · filed 2019-07-29 | $237.25M derived: sum of 3 quarters · filed 2021-02-05 | $297.65M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-03-31 | $87.50M 10-Q · filed 2020-05-06 | $87.54M 10-Q · filed 2019-04-29 | $156.45M derived: sum of 2 quarters · filed 2021-02-05 | $216.85M derived: sum of 3 quarters · filed 2021-02-05 | $277.76M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $68.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $129.35M derived: sum of 2 quarters · filed 2021-02-05 | $190.26M derived: sum of 3 quarters · filed 2021-02-05 | $248.90M 10-K · filed 2021-02-05 | $248.93M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $60.40M 10-Q · filed 2019-11-04 | $121.32M derived: sum of 2 quarters · filed 2019-11-04 | $179.95M 10-Q · filed 2019-11-04 | $236.26M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | $60.91M 10-Q · filed 2019-07-29 | $119.55M 10-Q · filed 2019-07-29 | $175.86M derived: sum of 3 quarters · filed 2020-02-07 | $219.73M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | $58.64M 10-Q · filed 2019-04-29 | $114.94M derived: sum of 2 quarters · filed 2020-02-07 | $158.82M derived: sum of 3 quarters · filed 2020-02-07 | $200.49M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $56.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $100.18M derived: sum of 2 quarters · filed 2020-02-07 | $141.86M derived: sum of 3 quarters · filed 2020-02-07 | $169.91M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | $43.87M 10-Q · filed 2018-11-05 | $85.55M derived: sum of 2 quarters · filed 2018-11-05 | $113.60M 10-Q · filed 2018-11-05 | $137.26M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-06-30 | $41.67M 10-Q · filed 2018-07-31 | $69.72M 10-Q · filed 2018-07-31 | $93.39M derived: sum of 3 quarters · filed 2019-02-08 | $110.89M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-03-31 | $28.05M 10-Q · filed 2018-04-30 | $51.72M derived: sum of 2 quarters · filed 2019-02-08 | $69.21M derived: sum of 3 quarters · filed 2019-02-08 | $84.18M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2016-12-31 | $23.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $41.16M derived: sum of 2 quarters · filed 2019-02-08 | $56.13M derived: sum of 3 quarters · filed 2019-02-08 | $68.08M 10-K · filed 2019-02-08 | ||||
| 2016-09-30 | $17.49M 10-Q · filed 2017-11-01 | $32.46M derived: sum of 2 quarters · filed 2017-11-01 | $44.41M 10-Q · filed 2017-11-01 | |||||
| 2016-06-30 | $14.96M 10-Q · filed 2017-08-03 | $26.92M 10-Q · filed 2017-08-03 | ||||||
| 2015-12-31 | $32.48M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |